Energy Fuels (TSX:EFR) Stock Trades At A Premium To Fair Value

Microsoft CEO Satya Nadella expects the bulk of artificial-intelligence use to migrate toward cheaper, increasingly interchangeable models. For Microsoft, that forecast cuts both ways: lower inference costs can improve the economics of Copilot, while falling token prices can make the company’s enormous infrastructure buildout harder to monetize.

Nadella told the Possible podcast that companies should not use frontier models for non-frontier problems. He argued that most token consumption will eventually become a commodity market supplied by a mix of open-weight and lower-cost proprietary models. Microsoft already follows that approach inside Copilot, routing work to cheaper models when the task does not require the most capable system.

That matters because every answer generated by Copilot carries a computing cost. Microsoft can protect the margin on paid software seats by matching each request with the least expensive model that can do the job reliably. The company said on its fiscal fourth-quarter call that its in-house MAI models reduced GPU costs by 89% for one Dynamics 365 feature and by as much as 84% for a PowerPoint feature.

The pressure is visible in Microsoft’s accounts. Companywide gross margin declined from 69.8% in fiscal 2024 to 67.9% in fiscal 2026, while Microsoft Cloud gross margin fell to 65% in the June 2026 quarter from 68% nine months earlier. Operating expenses grew just 7% in fiscal 2026 as revenue rose 18%, so operating margin still expanded. Cheaper inference is one way to keep that favorable operating leverage as Copilot use grows.

The other side of the strategy is Azure. Microsoft sells the infrastructure that generates tokens, and a more competitive market can push prices down even as demand rises. Property and equipment additions reached $115.95 billion in fiscal 2026, up from $64.55 billion a year earlier. The asset base therefore needs high utilization and durable demand, not merely higher token volumes.

Microsoft has substantial contracted demand. Commercial remaining performance obligations reached $678 billion at June 30, 2026, up 84% from a year earlier and 25% excluding OpenAI. That backlog offers visibility, but it also shows why customer concentration and the economics of OpenAI-related commitments remain important.

The next test arrives with Microsoft’s fiscal first-quarter report on October 28. Management guided Microsoft Cloud gross margin to remain near 65%. Holding that level while AI usage expands would support the case that model routing and in-house systems are offsetting infrastructure costs. Another decline would suggest that pricing and depreciation are still moving faster than the savings.

Olo has spent more than two decades powering restaurant orders behind the scenes. It is now using that network to reach diners directly with an app that promises restaurant menu prices, no sponsored listings and access to more than 250 brands at launch.

The Olo App, released on October 20, combines pickup and delivery ordering across national and regional chains. Olo says the app does not add menu-item markups, which it estimates can save diners an average of 15% to 30% per item compared with third-party delivery apps. Pickup orders can also avoid delivery fees, although ordinary taxes, service charges and delivery costs may still apply.

Olo’s commissioned survey illustrates the pitch. Seventy-four percent of respondents expected a delivery fee, but only 27% expected menu items themselves to cost more on third-party apps. The online survey covered 1,010 U.S. adults from October 14 through October 16 and had a stated margin of error of 3.1 percentage points. Because Olo commissioned the work, investors should treat it as evidence of the company’s positioning rather than independent proof of consumer behavior.

The company enters the consumer market with scale already embedded in restaurant systems. Olo says its platform serves more than 800 brands across more than 90,000 locations, supports over 3.5 million orders a day and reaches more than 100 million unique customers annually. Launch partners include Waffle House, Five Guys, Noodles & Company, First Watch, Dave’s Hot Chicken and several regional chains.

The app also avoids paid placement. Diners can follow restaurants to build a personalized feed, view nearby locations on a map and save payment and address details for repeat orders. Olo argues that this design preserves the direct relationship between a restaurant and its guests, an important distinction from marketplaces that control discovery and customer data.

This is a competitive development for delivery platforms, but it is not yet evidence of material damage to DoorDash or Uber. Olo did not disclose consumer adoption, order volume through the new app or the economics of delivery fulfillment. Its initial advantage is distribution through existing restaurant relationships; its challenge is persuading diners to open another app without the broad cross-merchant demand and courier networks of the established marketplaces.

Olo itself is no longer a public company. Thoma Bravo completed its $2 billion acquisition in September 2025, after which Olo’s shares ceased trading. The launch therefore creates no direct Olo stock catalyst. For public-market investors, the useful signal is whether restaurant-owned ordering can win repeat demand when menu pricing and customer control are more transparent.

ORIC Pharmaceuticals fell 22% after Johnson & Johnson presented early data for JNJ-78278343, also known as JNJ-6143, in heavily treated metastatic prostate cancer. The response rates were strong enough to create a real competitive threat, but the market reaction arrived before either program has produced the comparative evidence needed to establish a winner.

At the 50 milligram dose, 12 of 16 patients with measurable disease had a confirmed complete or partial response, a 75% rate. Across 38 patients, 77% achieved at least a 50% decline in prostate-specific antigen and 48% achieved at least a 90% decline. The patients had received a median of four prior treatment regimens, and 71% remained on treatment after a median follow-up of 5.6 months.

The safety data were encouraging but still preliminary. The most common treatment-related adverse events were elevated cholesterol in 18% of patients, nausea in 16% and elevated triglycerides in 16%. Four patients interrupted treatment, one required a dose reduction and one discontinued because of an adverse event. Johnson & Johnson plans to advance the drug into Phase 2 development.

Those results cannot be compared directly with ORIC’s rinzimetostat data. The programs are being tested in different patient populations, at different stages and with different combinations and follow-up periods. A high response rate in a small Phase 1 cohort can weaken expectations for a rival, but it does not establish superior progression-free survival, safety or durability.

ORIC has already started HIMALAYAS-1, a global Phase 3 trial of rinzimetostat plus darolutamide. The study plans to enroll about 600 patients at more than 250 sites in 25 countries and will compare the combination with a physician’s choice of another androgen-receptor inhibitor or docetaxel. That is a much harder clinical test than an early dose-expansion cohort.

The company also has financial runway to reach the readout. ORIC reported $387.6 million of cash, cash equivalents and investments at June 30, including $59.9 million of net proceeds raised through its at-the-market program. Management expects that capital to last into the second half of 2028 and beyond the Phase 3 primary endpoint.

ORIC’s second program adds another source of value and risk. In untreated HER2-mutant lung cancer, enozertinib produced an 84% investigator-assessed confirmed response rate among 25 evaluable patients and an 80% rate under blinded independent review. Sixty-five percent of treated patients had brain metastases. ORIC plans a roughly 360-patient Phase 3 study in the first half of 2027.

Johnson & Johnson’s data justify lowering the probability that rinzimetostat will face a lightly contested market. They do not justify treating ORIC’s program as already defeated. The decisive evidence will come from durability, safety and randomized outcomes, not from comparing response percentages across unrelated early studies.

Lululemon shares rose 7.8% on October 22 without a new company announcement, but the latest financial evidence did not change. Revenue is falling, North American demand remains weak and the reported profit included a large tariff refund that management does not expect to repeat.

In the quarter ended August 2, revenue declined 4% to $2.4 billion, or 5% in constant currency. Americas revenue fell 8%, while international revenue rose 4%. Comparable sales declined 9% globally, including a 12% drop in the Americas. Inventory fell 1% in dollars and 7% in units, which reduces some markdown risk but does not solve the traffic problem.

The profit figures require careful reading. Gross margin rose 200 basis points to 60.5%, yet the company received $134.5 million of tariff refunds that added 560 basis points to the quarter’s gross margin. Operating income declined 13% to $453.7 million, and operating margin fell 190 basis points to 18.8% even though the refunds added the same 560 basis points to operating margin. Diluted earnings per share was $2.92, down from $3.10, and included $0.86 from the refunds and associated interest after tax.

That one-time benefit matters because it is already embedded in the full-year outlook. Management expects fiscal 2026 revenue of $10.35 billion to $10.50 billion, a decline of 5% to 7%, and diluted EPS of $9.48 to $9.73. The earnings range includes the $0.86 refund benefit but assumes no additional refunds. For the third quarter, management projected revenue of $2.29 billion to $2.32 billion, down 10% to 11%, and EPS of $0.93 to $0.98.

The share price can rise because expectations were already low, because investors covered short positions or because buyers decided the valuation had become attractive. None of those explanations changes the operating test. Lululemon still needs to stabilize the Americas business without relying on one-time tariff benefits or heavy discounting.

The balance sheet provides time. Lululemon ended the quarter with $1.4 billion of cash and $593.7 million available under its revolving credit facility, and it repurchased $330 million of stock during the quarter. But financial capacity is not the same as a sales recovery.

The December report will show whether the third-quarter decline stayed within guidance and whether inventory discipline translated into healthier full-price sales. Until the company produces that evidence, the October rally is a market move rather than proof that the business has turned.

Nike shares have fallen sharply, but a lower stock price does not automatically make the business cheap. The company is still asking investors to pay for a turnaround while its revenue, margins and key lifestyle franchises lag stronger apparel peers.

Trefis calculated that Nike traded at 18.4 times trailing earnings on October 22. That was above Tapestry at 15.0 times, below Ralph Lauren at 23.4 times and well above lululemon at 8.3 times. The comparison is useful, but not perfect: the companies report on different fiscal calendars, sell different product mixes and carry different growth expectations. A price-to-earnings multiple alone cannot settle which stock is cheaper.

The operating gap is harder to dismiss. Nike reported fiscal first-quarter 2027 revenue of $11.2 billion, down 4% on a reported basis and 5% in constant currency. Diluted earnings per share fell to $0.48. Management expects fiscal 2027 revenue to decline by a high-single-digit percentage and adjusted diluted EPS of $1.15 to $1.35, excluding about $0.15 of restructuring expense.

Nike’s weakness is concentrated in important parts of the portfolio. NIKE Sportswear represented just under half of quarterly revenue and declined by a low-double-digit percentage. Management deliberately cut Dunk revenue by nearly 50%, creating an estimated $200 million headwind, as it reduced supply to protect full-price selling. Greater China revenue fell 26% as Nike exited discount-heavy digital channels and reset distribution. By contrast, the performance business built around sports such as running, football, tennis and golf grew by a high-single-digit percentage.

Peers show what the market is rewarding. Tapestry’s fiscal 2026 revenue rose 14% to $8.0 billion, led by Coach, and its non-GAAP operating margin reached 23.4%. Ralph Lauren reported a 17.5% GAAP operating margin in its latest quarter, while gross margin expanded to 73.7%. These companies are not direct substitutes for Nike, but their results demonstrate that premium brands can still grow and protect pricing in the same broad consumer environment.

The optimistic case is that Nike is intentionally accepting near-term revenue declines to rebuild demand, reduce discounting and restore product energy. The skeptical case is that those actions reveal deeper weakness in Sportswear and China that faster performance-product growth cannot yet offset.

Nike’s November investor day will matter more than a single valuation ratio. Investors need a credible timetable for Sportswear stabilization, evidence that wholesale order books are improving and a plan for Greater China that does not depend on returning to discount-driven sales. Until then, the stock’s lower multiple reflects a turnaround that remains unfinished, not an obviously mispriced leader.